High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab

High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab

Several studies have associated platelets (PLTs) to NSCLC prognosis. To understand the role of PLTs in immunotherapy-treated patients, we used blood samples of NSCLC patients at different TNM stage. We found that PLTs count and the expression of PD-L1 (pPD-L1) were significantly higher in NSCLC pati...

Full description

Bibliographic Details
Main Authors: Chiara Colarusso, Anna Falanga, Michela Terlizzi, Ilaria De Rosa, Pasquale Somma, Eduardo Maria Sommella, Vichy Caponigro, Luigi Panico, Emanuela Salviati, Pietro Campiglia, Giuseppe Salatiello, Teresa Tramontano, Piera Maiolino, Aldo Pinto, Rosalinda Sorrentino
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Non-small cell lung cancer (NSCLC)
Platelets (PLTs)
Immunotherapy
Survival rate
Tumor progression
Online Access:http://www.sciencedirect.com/science/article/pii/S075333222301507X

Internet

http://www.sciencedirect.com/science/article/pii/S075333222301507X

Similar Items